
Why late-stage pharma R&D processes need a rethink
Across pharma regulatory affairs, quality and pharmacovigilance/drug safety functions, process rigour is wedded tightly to SOPs. But these snapshot definitions of processes do not, of themselves, foster efficiency. In many cases, there has been a loss of sight of the deliverables. Here, Tobias Hitziger, Management Consultant at MAIN5… Read More












